1. Home
  2. AVNS vs TBPH Comparison

AVNS vs TBPH Comparison

Compare AVNS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVNS
  • TBPH
  • Stock Information
  • Founded
  • AVNS 2014
  • TBPH 2013
  • Country
  • AVNS United States
  • TBPH United States
  • Employees
  • AVNS N/A
  • TBPH N/A
  • Industry
  • AVNS Industrial Specialties
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVNS Health Care
  • TBPH Health Care
  • Exchange
  • AVNS Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • AVNS 591.9M
  • TBPH 699.0M
  • IPO Year
  • AVNS N/A
  • TBPH N/A
  • Fundamental
  • Price
  • AVNS $11.41
  • TBPH $14.37
  • Analyst Decision
  • AVNS
  • TBPH Strong Buy
  • Analyst Count
  • AVNS 0
  • TBPH 4
  • Target Price
  • AVNS N/A
  • TBPH $23.00
  • AVG Volume (30 Days)
  • AVNS 635.6K
  • TBPH 375.3K
  • Earning Date
  • AVNS 10-29-2025
  • TBPH 11-11-2025
  • Dividend Yield
  • AVNS N/A
  • TBPH N/A
  • EPS Growth
  • AVNS N/A
  • TBPH N/A
  • EPS
  • AVNS N/A
  • TBPH 0.26
  • Revenue
  • AVNS $692,500,000.00
  • TBPH $77,205,000.00
  • Revenue This Year
  • AVNS $0.25
  • TBPH $79.82
  • Revenue Next Year
  • AVNS $1.33
  • TBPH N/A
  • P/E Ratio
  • AVNS N/A
  • TBPH $56.20
  • Revenue Growth
  • AVNS 1.48
  • TBPH 24.49
  • 52 Week Low
  • AVNS $9.30
  • TBPH $7.88
  • 52 Week High
  • AVNS $23.68
  • TBPH $15.15
  • Technical
  • Relative Strength Index (RSI)
  • AVNS 43.33
  • TBPH 57.00
  • Support Level
  • AVNS $11.31
  • TBPH $14.17
  • Resistance Level
  • AVNS $12.00
  • TBPH $15.10
  • Average True Range (ATR)
  • AVNS 0.42
  • TBPH 0.47
  • MACD
  • AVNS -0.07
  • TBPH -0.05
  • Stochastic Oscillator
  • AVNS 12.82
  • TBPH 47.24

About AVNS Avanos Medical Inc.

Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: